Clinical, Cytogenetic and Molecular Characterization of a 96 MDS and AML Cohort with TP53 Mutation

被引：0
|
作者：
Duranjou, Marine [1 ]
Castoldi, Cecile [2 ]
Alary, Anne Sophie
Hicheri, Yosr [2 ]
Saillard, Colombe [2 ]
Rouzaud, Camille
Charbonnier, Aude [2 ]
Mohty, Bilal [2 ]
D'Incan, Evelyne [2 ]
Rey, Jerome [2 ]
Devillier, Raynier [3 ]
Vey, Norbert [4 ]
Gelsi-Boyer, Veronique [1 ]
Lhoumeau, Anne-Catherine [1 ]
Murati, Anne [1 ]
Golesi, Florence [1 ]
Mozziconacci, Marie Joelle [1 ]
Ittel, Antoine [1 ]
Garciaz, Sylvain [5 ]
机构：
[1] Inst Paoli Calmettes, Dept Biopathol, Marseille, France
[2] Inst Paoli Calmettes, Dept Hematol, Marseille, France
[3] Aix Marseille Univ, Inst Paoli Calmettes, Hematol & Transplantat, Marseille, France
[4] Aix Marseille Univ, Inst Paoli Calmettes, INSERM,U1068, CNRS,CRCM, Marseille, France
[5] Aix Marseille Univ, Hematol Dept, Integrat Struct & Chem Biol, Inserm,CNRS,Inst Paoli Calmettes,Ctr Rech Cancero, Marseille, France
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186086
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Molecular Characterization and Clinical Treatment of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) Patients With TP53 Mutation
    Li, Yanfen
    Wan, Hua
    Jing, Yu
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (12): : 841 - 851
  • [2] TP53 in MDS and AML: Biological and clinical advances
    Zhao, Yeqian
    Chen, Weihao
    Yu, Jing
    Pei, Shanshan
    Zhang, Qiang
    Shi, Jimin
    Huang, He
    Zhao, Yanmin
    CANCER LETTERS, 2024, 588
  • [3] TP53 Mutation Characteristics and Their Effects on Overall Survival in AML and MDS
    Puzo, Christian
    Hager, Karl
    Rinder, Henry
    Weinberg, Olga
    Siddon, Alexa
    LABORATORY INVESTIGATION, 2024, 104 (03) : S1468 - S1470
  • [4] Is TP53 Mutated AML the Same Disease as TP53 Mutated MDS?
    Valk, Peter J. M.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S3 - S5
  • [5] Comparison the Distinct Clinical Outcome with TP53 Mutation Status in MDS and AML :an Retrospective Study
    Xiang, Xinrong
    Ou, Yang
    Wu, Yu
    BLOOD, 2019, 134
  • [6] SIGNIFICANCE OF MOLECULAR AND CYTOGENETIC TP53 STATUS IN MDS WITH COMPLEX KARYOTYPES
    Ganster, C.
    Schaab, R.
    Shirneshan, K.
    Dierks, S.
    Martin, R.
    Germing, U.
    Palomo, L.
    Mies, A.
    Cisneros, A.
    Braulke, F.
    Hildebrandt, B.
    Kaivers, J.
    Platzbecker, U.
    Kroeger, N.
    Doehner, K.
    Glass, B.
    Nickelsen, M.
    Schanz, J.
    Bacher, U.
    Haase, D.
    LEUKEMIA RESEARCH, 2017, 55 : S108 - S109
  • [7] TP53 in AML and MDS: The new (old) kid on the block
    Marks, Jennifer A.
    Wang, Xin
    Fenu, Elena M.
    Bagg, Adam
    Lai, Catherine
    BLOOD REVIEWS, 2023, 60
  • [8] TP53 and the star-crossed lovers MDS and AML
    Welch, John S.
    BLOOD, 2022, 139 (15) : 2265 - 2266
  • [9] Transplant Outcomes for TP53 AML and MDS in a Contemporary Era
    Ozcan, Gonca
    Popat, Uday R.
    Kebriaei, Partow
    Alousi, Amin M.
    Alatrash, Gheath
    Bashir, Qaiser
    Mehta, Rohtesh S.
    Ramdial, Jeremy L.
    Rondon, Gabriela
    Shpall, Elizabeth J.
    Champlin, Richard E.
    Oran, Betul
    BLOOD, 2022, 140 : 10620 - 10621
  • [10] IMMUNOHISTOCHEMICAL AND CYTOGENETIC CORRELATION WITH TP53 MUTATIONS IN ACUTE MYELOID LEUKEMIA (AML) AND MYELODYSPLASTIC SYNDROME (MDS)
    Chai, J.
    Nwaoduah, N.
    Shi, Y.
    Verma, A.
    Gong, J.
    Wang, Y.
    LEUKEMIA RESEARCH, 2021, 108 : S23 - S24
12345